医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Terns Pharmaceuticals to Present at BioCentury’s 26th Annual Future Leaders in Biotech Industry Conference

2019年04月08日 PM06:00
このエントリーをはてなブックマークに追加


 

SAN MATEO, Calif. & SHANGHAI

Terns Pharmaceuticals Inc., a global biopharmaceutical company focused on discovering and developing molecularly targeted, oral, small-molecule drugs to treat NASH and cancer, today announced that Randy Halcomb, Ph.D., senior vice president of chemistry and early development, will present a corporate overview and update on the Company’s lead programs at BioCentury’s 26th Annual Future Leaders in the Biotech Industry Conference on Friday, April 12, 2018 at 2pm Eastern Time in room 404/405. The conference is being held at the Millennium Broadway Hotel in New York City.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company that is focused on the discovery and development of medicines for chronic liver disease and cancer. Based in China and the United States, the company is advancing a pipeline of small molecule drug candidates for the treatment of non-alcoholic steatohepatitis (NASH) and cancer, across multiple modalities. Terns leverages world class expertise in disease biology, medicinal chemistry, and clinical development, in order to bring promising new therapies to patients in China and other global markets.

For more information, visit www.ternspharma.com and www.ternspharma.com.cn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190408005272/en/

CONTACT

US Media Contact:
Margaret Robinson
(415) 690-0084

China Media Contact:
Xia Zou
+86 18523948668

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • 複合細胞療法による尿道狭窄治療で特許を取得
  • Taiwan’s COVID-19 response win applause, friendship from around the world
  • EUSA Pharma宣布FDA核准Silvoximab治疗COVID-19相关急性呼吸窘迫综合征住院患者的3期临床试验
  • 治疗尿道狭窄的混合细胞疗法获得日本专利
  • 有力保健機関がハンドドライヤーの使用を推奨